Seely Lynn
Known title: President and CEOCIK: 0001327111
Seely Lynn's purchase track record
Seely Lynn has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/14/2025 | LYEL | $106K | -16.8% | +9.6% | +16.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LYEL | ▼ Sell | Open Market | 9,589 | $149K | 8/21/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 390 | $6K | 8/10/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 388 | $7K | 5/11/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 7,455 | $174K | 2/11/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 438 | $10K | 2/10/2026 | View on chart |
| LYEL | ▲ Buy | Grant | 20,000 | $0 | 2/9/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 412 | $7K | 11/10/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 7,257 | $77K | 8/21/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 40,000 | $0 | 8/20/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 406 | $4K | 8/12/2025 | View on chart |
| LYEL | ▼ Sell | Open Market | 391 | $4K | 8/11/2025 | View on chart |
| LYEL | ▲ Buy | Open Market | 175,000 | $106K | 3/14/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 337,500 | $0 | 2/10/2025 | View on chart |
| LYEL | ▲ Buy | Grant | 200,000 | $0 | 2/9/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks
The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.